Applied DNA Sciences Announces Leadership Transition as CEO Dr. James Hayward Retires After 20-Year Tenure
核心洞察
Applied DNA Sciences (搜索) announced the retirement of Chairperson and CEO Dr. James A. Hayward effective June 18, 2025, following a distinguished 20-year term leading the biotechnology company.
President and COO Judy Murrah has been appointed as the new Chairperson of the Board of Directors and CEO, bringing over a decade of operational leadership at Applied DNA (搜索).
The leadership transition comes as Applied DNA (搜索) focuses on its biotherapeutic manufacturing capabilities and seeks to address manufacturing challenges in the nucleic acid therapeutics industry.
Applied DNA Sciences (搜索), Inc. (NASDAQ:APDN), a leader in PCR-based DNA (搜索) technologies, announced that Chairperson and Chief Executive Officer Dr. James A. Hayward is retiring from the Company and will step down from the Board of Directors effective June 18, 2025, following a distinguished 20-year term. During his tenure, Dr. Hayward was instrumental in transforming the Company's proprietary DNA production and detection technologies into commercial platforms, thereby establishing the foundation for Applied DNA's current market offerings.
New Leadership Appointment
The Board of Directors has appointed Judy Murrah to the roles of Chairperson, Board Director, and Chief Executive Officer in addition to retaining her current position as President. Ms. Murrah will lead the executive management team, which comprises Clay Shorrock, Chief Legal Officer and President of LineaRx (搜索), the Company's biotherapeutics subsidiary, and Beth Jantzen, Chief Financial Officer.
With over a decade of operational leadership at Applied DNA (搜索), Ms. Murrah has been influential in driving product commercialization, business scaling, and, more recently, the launch of the Company's GMP-compliant DNA manufacturing capabilities. She was previously with Symbol Technologies (搜索), where she played key roles in the company's growth from an early-stage company to an enterprise with approximately $2 billion in revenue and 5,000 employees, holding successive Vice President positions across Sales, Marketing, and Information Technology.
Following Symbol's acquisition by Motorola (搜索), Inc., she held strategic leadership roles at Motorola, overseeing critical financial management, quality, and program management initiatives during significant business transformations, mergers, acquisitions, and divestitures. Ms. Murrah is an inventor on 14 U.S. patents and holds an MBA from Harvard Business School.
Strategic Focus on Biotherapeutics Manufacturing
Board Director Robert C. Catell stated, "Judy has played an increasingly key role in recent years and has helped to grow who we are today as a company. Applied DNA (搜索) is poised for opportunity with an established biotherapeutic manufacturing capability that we believe is proven to address the manufacturing challenges identified by the industry. Driving it to deployment and scale with customers, partners, and regulators is our next mission, and the Board is confident that Judy's leadership will put the Company on the best path forward to maximize long-term shareholder value."
Ms. Murrah commented, "I am honored to take on the Chairperson and CEO roles and lead our associates and Applied DNA (搜索) forward at this important inflection point, as we focus on our most promising aspects of our businesses, drive increased operating efficiency, and navigate the current macro environment."
Company Operations and Technology Platforms
Applied DNA Sciences (搜索) operates as a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA (搜索)). Using the polymerase chain reaction (PCR) to enable both the production and detection of DNA, the company operates in two business markets: the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics (搜索) and the development and sale of a proprietary RNA polymerase (搜索) (RNAP) for use in the production of mRNA therapeutics; and the detection of DNA and RNA in molecular diagnostics and genetic testing services.
The company's forward-looking statements acknowledge risks including its history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future demand for its biotherapeutics products and services, and the fact that there has never been a commercial drug product utilizing the LineaDNA and/or IVT platforms approved for therapeutic use.